AA
VRTX icon

ALPS Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

ALPS Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Sell
2,268
-230
-9% -$107K ﹤0.01% 583
2025
Q4 		$1.13M Buy
2,498
+99
+4% +$42.7K 0.01% 527
2025
Q3 		$940K Buy
2,399
+1,160
+94% +$485K 0.01% 520
2025
Q2 		$552K Sell
1,239
-78
-6% -$35.9K ﹤0.01% 612
2025
Q1 		$639K Buy
1,317
+529
+67% +$247K ﹤0.01% 555
2024
Q4 		$317K Sell
788
-17
-2% -$7.88K ﹤0.01% 857
2024
Q3 		$374K Sell
805
-1,327
-62% -$637K ﹤0.01% 718
2024
Q2 		$999K Buy
2,132
+80
+4% +$34.7K 0.01% 463
2024
Q1 		$858K Sell
2,052
-291
-12% -$123K 0.01% 519
2023
Q4 		$953K Sell
2,343
-311
-12% -$115K 0.01% 492
2023
Q3 		$923K Buy
2,654
+183
+7% +$64K 0.01% 484
2023
Q2 		$870K Buy
2,471
+839
+51% +$283K 0.01% 520
2023
Q1 		$514K Sell
1,632
-995
-38% -$298K ﹤0.01% 589
2022
Q4 		$759K Sell
2,627
-120
-4% -$36.6K 0.01% 525
2022
Q3 		$795K Buy
2,747
+411
+18% +$118K 0.01% 514
2022
Q2 		$658K Buy
2,336
+97
+4% +$26K 0.01% 535
2022
Q1 		$584K Sell
2,239
-792
-26% -$188K 0.01% 412
2021
Q4 		$666K Sell
3,031
-354
-10% -$68.8K 0.01% 451
2021
Q3 		$614K Buy
3,385
+1,614
+91% +$315K 0.01% 474
2021
Q2 		$357K Sell
1,771
-63
-3% -$13.2K ﹤0.01% 673
2021
Q1 		$394K Sell
1,834
-1,432
-44% -$315K ﹤0.01% 518
2020
Q4 		$772K Sell
3,266
-272
-8% -$62.4K 0.01% 417
2020
Q3 		$963K Buy
3,538
+1,323
+60% +$365K 0.01% 358
2020
Q2 		$643K Buy
2,215
+1,149
+108% +$312K 0.01% 411
2020
Q1 		$254K Sell
1,066
-921
-46% -$211K ﹤0.01% 557
2019
Q4 		$435K Sell
1,987
-87
-4% -$17.6K ﹤0.01% 532
2019
Q3 		$351K Sell
2,074
-21
-1% -$3.71K ﹤0.01% 742
2019
Q2 		$384K Sell
2,095
-112
-5% -$19.6K ﹤0.01% 685
2019
Q1 		$406K Buy
+2,207
New +$408K ﹤0.01% 670

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ALPS Advisors's VRTX Position: Q1 2026 in Review

ALPS Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 9.2% in Q1 2026, selling an estimated $107K and leaving 2,268 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #583.

ALPS Advisors first reported a position in VRTX in Q1 2019 and has held it in 29 quarters since. The position peaked at $1.13M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • ALPS Advisors held 2,268 shares of Vertex Pharmaceuticals worth $1.01M as of Q1 2026.
  • ALPS Advisors sold 230 Vertex Pharmaceuticals shares in Q1 2026, an estimated $107K.
  • Vertex Pharmaceuticals made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #583 holding.
  • ALPS Advisors first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • ALPS Advisors's Vertex Pharmaceuticals position peaked at $1.13M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.